Home / GU oncology / Prostate / Adjuvant RT post-prostatectomy

Prostate → Adjuvant radiotherapy after prostatectomy

Last reviewed: 2026-09-22 · Next review: 2026-12-21

current — modern trials support surveillance with early salvage radiotherapy for the studied population rather than routine adjuvant radiotherapy

Who this applies to

Population	Trial criteria or boundary	Decision implication
Adverse pathology after radical prostatectomy with PSA ≤0.2 ng/mL	RADICALS-RT, RAVES, and GETUG-AFU 17 randomized within roughly 22 weeks after surgery¹²³.	Surveillance and protocol-defined early salvage are the direct modern-trial comparison⁴.
Persistent PSA, pathologic node-positive disease, or known metastatic disease	Outside the modern ART-versus-early-salvage population⁴.	Use a setting-specific salvage/intensification discussion; do not import this result unchanged⁴⁶.

Standard options

Clinical context	Option	Key inclusion	Typical course
Adverse pathology with undetectable PSA	PSA surveillance with early salvage radiotherapy if indicated⁴	Modern ARTISTIC-type population⁴.	Trigger and field individualized to PSA kinetics, pathology, and imaging⁴⁶.
Selected exceptional postoperative risk	Adjuvant radiotherapy after multidisciplinary discussion⁵⁶	Do not treat the randomized evidence as a blanket rule for persistent PSA or pN+ disease⁴.	Individualized⁵⁶.

Therapy sequencing

Postoperative state	Treatment order	Evidence boundary
Adverse pathology with undetectable PSA	PSA surveillance → early salvage radiotherapy if recurrence criteria are met⁴.	This is the modern randomized comparison and does not apply unchanged to persistent PSA or pN+ disease⁴.
Persistent PSA, nodal disease, or imaging-detected recurrence	Enter the early-salvage/intensification pathway rather than routine-adjuvant evidence⁶.	These states were outside the modern ART-versus-early-salvage trial population⁴.
Exceptional postoperative risk after multidisciplinary review	Consider adjuvant radiotherapy⁵⁶.	ART is not a blanket sequence; balance recurrence risk against durable urinary and sexual toxicity¹²³.

Surveillance and treatment de-escalation

Setting	PSA	Imaging	Stop/de-escalate	Re-escalate
Post-prostatectomy surveillance (preferred)⁴⁶	Every 3–6 months within the first 2 years, then every 6 months through 5 years; testosterone if ADT ever used⁵⁶⁷.	As clinically indicated for symptoms or rising PSA; staging before salvage when triggered⁴⁶.	Do not deliver routine adjuvant radiotherapy when PSA is undetectable in the ARTISTIC population; observation with protocol-defined early salvage is the modern comparison⁴.	PSA rise above institutional early-salvage trigger → salvage radiotherapy pathway while PSA remains low⁴⁶.
Selected adjuvant radiotherapy¹⁵	Every 3–6 months¹⁵.	As clinically indicated; urinary and sexual toxicity assessment alongside PSA¹⁵.	Complete planned radiotherapy course; hold only for acute toxicity¹.	Biochemical or imaging progression → salvage intensification or systemic therapy⁵⁶.

AUA/ASTRO/SUO support early salvage when PSA rises rather than automatic adjuvant radiotherapy for the studied adverse-pathology, undetectable-PSA population⁶.

Published 5-year EFS 89% vs 88% (adjuvant vs early-salvage policy); not a full KM reconstruction⁴.

Landmark evidence

Trial	Population	Intervention	Comparator	Primary endpoint	Clinically meaningful outcomes	Generalizability-critical differences
RADICALS-RT, N=1,396	≥1 adverse feature after prostatectomy¹	Adjuvant prostate-bed radiotherapy¹	Observation with salvage-policy radiotherapy¹	Freedom from distant metastasis¹	Ten-year FFDM 93% vs 90%; HR 0.68 (0.43–1.07); OS HR 0.98¹.	Includes varied adverse features; not a persistent-PSA strategy¹.
RAVES, N=333	Margin positivity, extraprostatic extension, or seminal-vesicle invasion; PSA ≤0.10²	Adjuvant radiotherapy²	Early salvage radiotherapy²	Five-year freedom from biochemical progression²	86% vs 87%; salvage/adjuvant HR 1.12 (0.65–1.90)².	Did not meet prespecified noninferiority because events were fewer than expected².
GETUG-AFU 17	pT3–4a/R1, pN0/x; all received 6 months triptorelin³	Adjuvant radiotherapy plus triptorelin³	Early salvage radiotherapy plus triptorelin³	Event-free survival³	Five-year EFS 92% vs 90%; HR 0.81 (0.48–1.36)³.	Hormone therapy in both arms; not a radiation-alone comparison³.
ARTISTIC, N=2,153	Meta-analysis of the three modern trials⁴	Adjuvant-radiotherapy policy⁴	Early-salvage policy⁴	Event-free survival⁴	Five-year EFS 89% vs 88%; HR 0.95 (0.75–1.21)⁴.	Only 39% in the early-salvage-policy group had started radiotherapy at analysis⁴.

Biomarkers

Marker	Current clinic role	Emerging / investigational	How it changes decision now	Limits
Postoperative PSA	Defines the undetectable-PSA trial boundary¹²⁴	—	Undetectable PSA supports observation with early salvage; persistent PSA needs a salvage rather than routine-adjuvant discussion⁴⁶.	Persistent PSA, pN+, or known metastases were outside the modern ART-versus-early-salvage population⁴.
Pathology (Grade Group, SVI, margins, pN)	Recurrence-risk assessment¹²³	—	Margin, grade, extracapsular extension, and seminal-vesicle invasion characterize risk and inform salvage timing discussion¹²³⁴.	These features do not mandate routine ART in the modern-trial population⁴.
PSMA PET	Staging information when PSA rises or salvage is planned⁵⁶	Expanding use at low PSA for target definition⁵⁶	May refine salvage planning when recurrence is suspected; does not by itself mandate adjuvant RT while PSA is undetectable⁴⁶.	Not a validated selector for routine adjuvant radiotherapy in the ARTISTIC population⁴.
Germline testing	Hereditary-risk counseling when indicated⁵	Broader panels for later-line planning⁵	Informs genetic counseling; does not select adjuvant vs early-salvage policy on this page⁴⁵.	Not an ART-versus-salvage treatment selector in the source pack⁴⁵.

Upcoming research

Field direction: PET-M0 node-positive disease with detectable PSA is the main intensification experiment after prostatectomy⁹.

Trial	Why it may change care	Evidence status
NRG-GU008 / INNOVATE	Tests pelvis/prostate-bed radiotherapy plus 24 months hormone therapy with or without apalutamide in PET-M0, pN+ disease with detectable PSA⁹.	Phase 3, active not recruiting; MFS primary endpoint; no efficacy results⁹.

Toxicity

Regimen and comparator	Trial-level safety outcomes	Selected named toxicities	Counseling focus
Adjuvant versus early-salvage radiotherapy, RADICALS-RT	Grade 3–4 urethral stricture within 2 years: 6% vs 4%¹.	One-year urinary incontinence 5.3% vs 2.7%¹.	Review urinary leakage, obstruction, hematuria, bowel change, and sexual dysfunction; contact the team for retention or heavy bleeding¹.
Adjuvant versus early-salvage radiotherapy, RAVES	Grade ≥2 GU toxicity: 70% vs 54%².	The retrieved abstract does not provide named-event percentages².	Counsel on urinary and sexual effects and avoid adding unverified event-level rates².
Adjuvant versus early-salvage radiotherapy, GETUG-AFU 17	Late grade ≥2 GU toxicity: 59% vs 22%³.	Late grade ≥2 erectile dysfunction: 28% vs 8%³.	Discuss durable urinary and erectile effects before choosing treatment timing³.

On-treatment monitoring

SOC/option regimen	Hallmark monitoring toxicity and published rate	Patient action / clinic response
Adjuvant or early-salvage prostate-bed radiotherapy	RADICALS-RT: grade 3–4 urethral stricture within two years 6% vs 4%; one-year urinary incontinence 5.3% vs 2.7%¹.	Monitor urinary leakage, obstruction, retention, hematuria, bowel change, and sexual function; retention or heavy bleeding requires prompt contact¹.
Radiotherapy plus six months of triptorelin in GETUG-AFU 17	Late grade ≥2 GU toxicity 59% vs 22%; late grade ≥2 erectile dysfunction 28% vs 8%³.	Review urinary, bowel, erectile, hot-flash, fatigue, metabolic, and bone symptoms; retention, heavy bleeding, or severe bowel symptoms needs prompt contact³.

Epic phrase

#postprostatectomyart

Counseling: Modern trials (ARTISTIC meta-analysis) showed similar 5-year event-free survival with adjuvant vs early-salvage radiotherapy policy (about 89% vs 88%; HR 0.95 vs early salvage). RADICALS-RT 10-year freedom from distant metastasis 93% vs 90% with early-salvage policy (HR 0.68 vs early salvage, CI crossed 1). Observation with early salvage at low PSA is preferred for undetectable PSA after adverse pathology.
Counseling: Reviewed surveillance and de-escalation: PSA every 3–6 months within the first 2 years, then every 6 months through 5 years when observing after adverse pathology with undetectable PSA; early salvage RT at low PSA rise rather than routine adjuvant RT for the modern-trial population (ARTISTIC published 5-year EFS about 89% vs 88% for adjuvant vs early-salvage policy; not a full KM curve); persistent PSA or pN+ needs separate intensification discussion.
Monitoring: During radiotherapy, review urinary leakage/obstruction, retention, hematuria, bowel change, and sexual function; if triptorelin is used, also review hot flashes, fatigue, metabolic, and bone effects. Contact the team for urinary retention, heavy hematuria, or new severe bowel symptoms; late urinary and erectile effects can persist.
Decision: *** selects PSA surveillance with early salvage planning / adjuvant radiotherapy after multidisciplinary review.
Labs/NGS: PSA *; postoperative pathology *; genomic classifier *** only if it will inform a documented decision.
Procedures: *** radiation-oncology consultation and imaging plan.
Follow-up: *** PSA timing, symptom assessment, and salvage trigger.

Edit markdown

Guideline references

Sources

Changelog

2026-09-22: Explicit Setting×PSA×Imaging surveillance table; inserted ARTISTIC 5-year EFS landmark figure; expanded Biomarkers to five-column clinic/emerging format.
2026-09-22: Renamed Upcoming trial results to Upcoming research; reframed for ongoing trials and field direction.
2026-09-22: Named comparator arms in paired dotphrase counseling for efficacy/toxicity rates.
2026-09-22: Added line-level source superscripts ([^n]) linked to numbered Sources.
2026-09-22: Added Surveillance and treatment de-escalation section; strengthened quantified benefit counseling in dotphrase.

2026-09-21: Added postoperative therapy sequencing and radiotherapy/ADT on-treatment monitoring.
2026-09-21: Created postoperative adjuvant-radiotherapy setting page with modern adjuvant-versus-early-salvage evidence.

Edit evidence markdown

Evidence page